Olokizumab

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameOlokizumab
Drug Alias NameAnti-IL6-UCBCDP-6038
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 inhibitors
TargetsInterleukin-6
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lung Diseases, InterstitialCrohn Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm JscR-Pharm International Llc
Inactive CompaniesUcb PharmaUcb Biosciences GmbhUcb Japan Co Ltd +[4] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Lung Diseases, InterstitialArthritis, Rheumatoid +[4] 
Inactive IndicationsCrohn DiseaseArthritis

Other Information

ATC CodeN/A
Related LinksWikipedia